FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia ESMO Calls for Cancer Care Integration in EU Global Health Resilience Initiative (GHRI) FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer MOST POPULAR Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... November 3, 2020 ctDNA Monitoring Improves Early Relapse Detection After Treatment with Axicabtagene Ciloleucel... June 22, 2021 NHL Player Carey Price Surprises 11-Year-Old Boy Who Just Lost Mom... June 24, 2019 POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to... May 17, 2023 Load more HOT NEWS Medicare Advantage Plans: Read the Fine Print ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to... Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other...
